tiprankstipranks
Trending News
More News >
Elevance Health (ELV)
NYSE:ELV
US Market

Elevance Health (ELV) Stock Forecast & Price Target

Compare
2,497 Followers
See the Price Targets and Ratings of:

ELV Analyst Ratings

Strong Buy
15Ratings
Strong Buy
12 Buy
3 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$494.87
▲(30.20%Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $494.87 with a high forecast of $585.00 and a low forecast of $428.00. The average price target represents a 30.20% change from the last price of $380.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"366":"$366","421":"$421","476":"$476","531":"$531","586":"$586"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":585,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$585.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":494.87,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$494.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":428,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$428.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[366,421,476,531,586],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,377.05,393.04615384615386,409.0423076923077,425.03846153846155,441.0346153846154,457.03076923076924,473.0269230769231,489.0230769230769,505.0192307692308,521.0153846153846,537.0115384615385,553.0076923076923,569.0038461538461,{"y":585,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,377.05,386.11307692307696,395.17615384615385,404.2392307692308,413.3023076923077,422.36538461538464,431.42846153846153,440.4915384615385,449.5546153846154,458.6176923076923,467.6807692307692,476.74384615384616,485.8069230769231,{"y":494.87,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,377.05,380.96923076923076,384.88846153846157,388.8076923076923,392.7269230769231,396.6461538461539,400.56538461538463,404.4846153846154,408.40384615384613,412.32307692307694,416.2423076923077,420.16153846153844,424.08076923076925,{"y":428,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":530.84,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":528.56,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":526.26,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":550.65,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":507.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":410.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":407.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":367.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":394.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":395.22,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":432.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":377.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$585.00Average Price Target$494.87Lowest Price Target$428.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ELV
TipRanks AITipRanks
Not Ranked
TipRanks
$415
Buy
9.19%
Upside
Reiterated
05/14/25
Elevance Health's overall score of 71 reflects a strong financial foundation with consistent revenue growth and solid profitability, though offset by technical weaknesses and challenges in the Medicaid segment. Valuation is fair, but not compelling enough alone to drive a strong buy recommendation. The earnings call provided positive strategic updates, yet acknowledged ongoing cost pressures. Overall, this positions Elevance Health as a stable investment with areas for improvement, especially in technical momentum and cost management.
Cantor Fitzgerald Analyst forecast on ELV
Sarah JamesCantor Fitzgerald
Cantor Fitzgerald
$485
Buy
27.61%
Upside
Reiterated
06/04/25
Cantor Fitzgerald Sticks to Their Buy Rating for Elevance Health (ELV)
RBC Capital Analyst forecast on ELV
Ben HendrixRBC Capital
RBC Capital
$478
Buy
25.77%
Upside
Reiterated
06/03/25
RBC Capital Remains a Buy on Elevance Health (ELV)
Barclays
$522$480
Buy
26.29%
Upside
Reiterated
06/03/25
Elevance Health price target lowered to $480 from $522 at BarclaysElevance Health price target lowered to $480 from $522 at Barclays
Wells Fargo Analyst forecast on ELV
Stephen BaxterWells Fargo
Wells Fargo
$478
Buy
25.77%
Upside
Reiterated
05/28/25
Wells Fargo Sticks to Their Buy Rating for Elevance Health (ELV)
Truist Financial Analyst forecast on ELV
David S MacdonaldTruist Financial
Truist Financial
$510
Buy
34.19%
Upside
Reiterated
05/01/25
Elevance Health (ELV) Gets a Buy from Truist Financial
Argus Research Analyst forecast on ELV
David ToungArgus Research
Argus Research
$465
Buy
22.35%
Upside
Reiterated
04/24/25
Argus Research Keeps Their Buy Rating on Elevance Health (ELV)
Jefferies Analyst forecast on ELV
David WindleyJefferies
Jefferies
$461$488
Buy
28.40%
Upside
Reiterated
04/23/25
Positive Outlook for Elevance Health: Buy Rating Supported by Medicaid Rate Updates and Strategic Moves
Bernstein Analyst forecast on ELV
Lance WilkesBernstein
Bernstein
$585
Buy
53.92%
Upside
Reiterated
04/23/25
Bernstein reiterates Outperform on Elevance (ELV); Strong Growth in CarelonBernstein SocGen Group analyst Lance Wilkes reiterated an Outperform rating and $585.00 price target on Elevance (NYSE: ELV).
TD Cowen
$484
Buy
27.34%
Upside
Reiterated
04/23/25
Buy Rating for Elevance Health: Stable Medicaid and Medicare Advantage Outlook with Potential Upside
Leerink Partners Analyst forecast on ELV
Whit MayoLeerink Partners
Leerink Partners
$463$510
Buy
34.19%
Upside
Reiterated
04/22/25
Elevance Health's Growth Potential Justifies Buy Rating Amid Sector Challenges
Bank of America Securities Analyst forecast on ELV
Joanna GajukBank of America Securities
Bank of America Securities
$465$480
Hold
26.29%
Upside
Reiterated
04/22/25
Elevance Health: Hold Rating Amid Medicare Cost Pressures and Regulatory Risks
Morgan Stanley Analyst forecast on ELV
Erin WrightMorgan Stanley
Morgan Stanley
$405$428
Hold
12.61%
Upside
Reiterated
04/15/25
Elevance Health price target raised to $428 from $405 at Morgan StanleyElevance Health price target raised to $428 from $405 at Morgan Stanley
Robert W. Baird Analyst forecast on ELV
Michael HaRobert W. Baird
Robert W. Baird
$625$529
Hold
39.18%
Upside
Downgraded
04/14/25
Elevance Health downgraded to Neutral from Outperform at BairdElevance Health downgraded to Neutral from Outperform at Baird
Mizuho Securities Analyst forecast on ELV
Ann HynesMizuho Securities
Mizuho Securities
$455$505
Buy
32.87%
Upside
Reiterated
04/09/25
Elevance Health price target raised to $505 from $455 at MizuhoElevance Health price target raised to $505 from $455 at Mizuho
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ELV
TipRanks AITipRanks
Not Ranked
TipRanks
$415
Buy
9.19%
Upside
Reiterated
05/14/25
Elevance Health's overall score of 71 reflects a strong financial foundation with consistent revenue growth and solid profitability, though offset by technical weaknesses and challenges in the Medicaid segment. Valuation is fair, but not compelling enough alone to drive a strong buy recommendation. The earnings call provided positive strategic updates, yet acknowledged ongoing cost pressures. Overall, this positions Elevance Health as a stable investment with areas for improvement, especially in technical momentum and cost management.
Cantor Fitzgerald Analyst forecast on ELV
Sarah JamesCantor Fitzgerald
Cantor Fitzgerald
$485
Buy
27.61%
Upside
Reiterated
06/04/25
Cantor Fitzgerald Sticks to Their Buy Rating for Elevance Health (ELV)
RBC Capital Analyst forecast on ELV
Ben HendrixRBC Capital
RBC Capital
$478
Buy
25.77%
Upside
Reiterated
06/03/25
RBC Capital Remains a Buy on Elevance Health (ELV)
Barclays
$522$480
Buy
26.29%
Upside
Reiterated
06/03/25
Elevance Health price target lowered to $480 from $522 at BarclaysElevance Health price target lowered to $480 from $522 at Barclays
Wells Fargo Analyst forecast on ELV
Stephen BaxterWells Fargo
Wells Fargo
$478
Buy
25.77%
Upside
Reiterated
05/28/25
Wells Fargo Sticks to Their Buy Rating for Elevance Health (ELV)
Truist Financial Analyst forecast on ELV
David S MacdonaldTruist Financial
Truist Financial
$510
Buy
34.19%
Upside
Reiterated
05/01/25
Elevance Health (ELV) Gets a Buy from Truist Financial
Argus Research Analyst forecast on ELV
David ToungArgus Research
Argus Research
$465
Buy
22.35%
Upside
Reiterated
04/24/25
Argus Research Keeps Their Buy Rating on Elevance Health (ELV)
Jefferies Analyst forecast on ELV
David WindleyJefferies
Jefferies
$461$488
Buy
28.40%
Upside
Reiterated
04/23/25
Positive Outlook for Elevance Health: Buy Rating Supported by Medicaid Rate Updates and Strategic Moves
Bernstein Analyst forecast on ELV
Lance WilkesBernstein
Bernstein
$585
Buy
53.92%
Upside
Reiterated
04/23/25
Bernstein reiterates Outperform on Elevance (ELV); Strong Growth in CarelonBernstein SocGen Group analyst Lance Wilkes reiterated an Outperform rating and $585.00 price target on Elevance (NYSE: ELV).
TD Cowen
$484
Buy
27.34%
Upside
Reiterated
04/23/25
Buy Rating for Elevance Health: Stable Medicaid and Medicare Advantage Outlook with Potential Upside
Leerink Partners Analyst forecast on ELV
Whit MayoLeerink Partners
Leerink Partners
$463$510
Buy
34.19%
Upside
Reiterated
04/22/25
Elevance Health's Growth Potential Justifies Buy Rating Amid Sector Challenges
Bank of America Securities Analyst forecast on ELV
Joanna GajukBank of America Securities
Bank of America Securities
$465$480
Hold
26.29%
Upside
Reiterated
04/22/25
Elevance Health: Hold Rating Amid Medicare Cost Pressures and Regulatory Risks
Morgan Stanley Analyst forecast on ELV
Erin WrightMorgan Stanley
Morgan Stanley
$405$428
Hold
12.61%
Upside
Reiterated
04/15/25
Elevance Health price target raised to $428 from $405 at Morgan StanleyElevance Health price target raised to $428 from $405 at Morgan Stanley
Robert W. Baird Analyst forecast on ELV
Michael HaRobert W. Baird
Robert W. Baird
$625$529
Hold
39.18%
Upside
Downgraded
04/14/25
Elevance Health downgraded to Neutral from Outperform at BairdElevance Health downgraded to Neutral from Outperform at Baird
Mizuho Securities Analyst forecast on ELV
Ann HynesMizuho Securities
Mizuho Securities
$455$505
Buy
32.87%
Upside
Reiterated
04/09/25
Elevance Health price target raised to $505 from $455 at MizuhoElevance Health price target raised to $505 from $455 at Mizuho
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

1 Month
xxx
Success Rate
13/23 ratings generated profit
57%
Average Return
+0.87%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.52% of your transactions generating a profit, with an average return of +0.87% per trade.
3 Months
xxx
Success Rate
22/39 ratings generated profit
56%
Average Return
+0.76%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.41% of your transactions generating a profit, with an average return of +0.76% per trade.
1 Year
Success Rate
20/27 ratings generated profit
74%
Average Return
+18.90%
reiterated a buy rating 8 months ago
Copying A.J. Rice's trades and holding each position for 1 Year would result in 74.07% of your transactions generating a profit, with an average return of +18.90% per trade.
2 Years
xxx
Success Rate
24/27 ratings generated profit
89%
Average Return
+44.48%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +44.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
0
0
0
0
0
Buy
18
18
22
25
25
Hold
5
5
5
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
23
27
29
29
In the current month, ELV has received 25 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 494.87.
Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $9.25 with a range of $8.61 to $9.98. The previous quarter’s EPS was $11.97. ELV beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.
Next quarter’s earnings estimate for ELV is $9.25 with a range of $8.61 to $9.98. The previous quarter’s EPS was $11.97. ELV beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $48.14B with a range of $46.79B to $49.72B. The previous quarter’s sales results were $48.89B. ELV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.
Next quarter’s sales forecast for ELV is $48.14B with a range of $46.79B to $49.72B. The previous quarter’s sales results were $48.89B. ELV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year ELV has Outperformed its overall industry.

ELV Stock Forecast FAQ

What is ELV’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is 494.87.
    What is ELV’s upside potential, based on the analysts’ average price target?
    Elevance Health has 30.20% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ELV a Buy, Sell or Hold?
          Elevance Health has a consensus rating of Strong Buy which is based on 12 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Elevance Health’s price target?
            The average price target for Elevance Health is 494.87. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $585.00 ,the lowest forecast is $428.00. The average price target represents 30.20% Increase from the current price of $380.07.
              What do analysts say about Elevance Health?
              Elevance Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of ELV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis